$XERI
XERIANT, INC. Stock $xeri

$xeri Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000147793221008723 Filed on November 22, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.167M	$1.800M	$35.97K
YoY Change	9.61%	4903.05%	215.8%
% of Gross Profit
Research & Development	$2.860M	$2.341M	$0.00
YoY Change			-100.0%
% of Gross Profit
Depreciation & Amortization	$80.00
YoY Change
% of Gross Profit
Operating Expenses	$4.260M	$4.252M	$93.07K
YoY Change	280.11%	4468.83%	424.93%
Operating Profit	-$4.260M	-$4.252M	-$93.07K
YoY Change	280.11%	4468.83%
Interest Expense	$1.625K	$2.389K	$1.087K
YoY Change	42.67%	119.78%	-176.01%
% of Operating Profit
Other Income/Expense, Net	-$1.267M	-$195.7K	-$234.0K
YoY Change	1643.76%	-16.37%
Pretax Income	-$5.526M	-$4.448M	-$327.1K
YoY Change	363.11%	1259.93%	1606.16%
Income Tax
% Of Pretax Income
Net Earnings	-$5.526M	-$4.448M	-$327.1K
YoY Change	363.11%	1259.92%	1606.17%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.02
Diluted Earnings Per Share	-$9.891K	-$14.50K	-$2.763K
COMMON SHARES
Basic Shares Outstanding	322.6M shares	225.5M shares
Diluted Shares Outstanding		225.5M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.111M	$281.9K	$42.06K
YoY Change	10646.18%	570.11%	-75.23%
Cash & Equivalents	$2.111M	$281.8K	$42.06K
Short-Term Investments
Other Short-Term Assets	$15.37K	$48.64K	$13.32K
YoY Change	12.85%	265.17%
Inventory
Prepaid Expenses	$2.823K
Receivables
Other Receivables
Total Short-Term Assets	$2.126M	$330.5K	$55.38K
YoY Change	6291.82%	496.75%	-67.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.907K	$159.4K	$197.2K
YoY Change	-97.39%	-19.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$154.2K	$159.4K	$197.2K
YoY Change	-18.02%	-19.19%
TOTAL ASSETS
Total Short-Term Assets	$2.126M	$330.5K	$55.38K
Total Long-Term Assets	$154.2K	$159.4K	$197.2K
Total Assets	$2.280M	$489.9K	$252.6K
YoY Change	929.96%	93.92%	48.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$23.74K	$26.18K	$26.81K
YoY Change	-20.87%	-2.35%	-46.33%
Accrued Expenses	$30.00K	$27.50K	$50.32K
YoY Change	-49.34%	-45.35%	2759.09%
Deferred Revenue
YoY Change
Short-Term Debt	$721.1K	$139.7K	$29.05K
YoY Change	3035.04%	380.79%	-86.86%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$820.5K	$237.5K	$106.2K
YoY Change	652.77%	123.69%	-61.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$117.6K	$129.7K	$173.8K
YoY Change	-28.0%	-25.4%
Total Long-Term Liabilities	$117.6K	$129.7K	$173.8K
YoY Change	-28.0%	-25.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$820.5K	$237.5K	$106.2K
Total Long-Term Liabilities	$117.6K	$129.7K	$173.8K
Total Liabilities	$938.1K	$367.2K	$280.0K
YoY Change	244.5%	31.14%	2.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.03M
YoY Change
Common Stock	$3.577K	$3.221K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.342M	$122.7K	-$27.40K
YoY Change
Total Liabilities & Shareholders Equity	$2.280M	$489.9K	$252.6K
YoY Change	929.96%	93.92%	48.77%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$5.526M	-$4.448M	-$327.1K
YoY Change	363.11%	1259.92%	1606.17%
Depreciation, Depletion And Amortization	$80.00
YoY Change
Cash From Operating Activities	-$3.285M	-$2.728M	-$76.14K
YoY Change	3701.5%	3482.77%	295.92%
INVESTING ACTIVITIES
Capital Expenditures	-$4.990K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$4.990K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.669M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.119M	$2.047M	$79.30K
YoY Change	7898.36%	2481.45%	-57.37%
NET CHANGE
Cash From Operating Activities	-3.285M	-$2.728M	-$76.14K
Cash From Investing Activities	-4.990K	$0.00
Cash From Financing Activities	5.119M	$2.047M	$79.30K
Net Change In Cash	1.829M	-$680.7K	$3.165K
YoY Change	-8256.56%	-21605.59%	-98.1%
FREE CASH FLOW
Cash From Operating Activities	-$3.285M	-$2.728M	-$76.14K
Capital Expenditures	-$4.990K	$0.00
Free Cash Flow	-$3.280M	-$2.728M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	322574504	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	281847	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	962540	USD
CY2021Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12546	USD
CY2021Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	12546	USD
CY2021Q3	xeri	Prepaids Prepaids	36088	USD
CY2021Q2	xeri	Prepaids Prepaids	1234	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	330481	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	976320	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	159387	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169209	USD
CY2021Q3	us-gaap	Assets Assets	489868	USD
CY2021Q2	us-gaap	Assets Assets	1145529	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	26180	USD
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	73224	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27500	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25000	USD
CY2021Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	139674	USD
CY2021Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	158196	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44159	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	42643	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	237513	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	299063	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129667	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	141160	USD
CY2021Q3	us-gaap	Liabilities Liabilities	367180	USD
CY2021Q2	us-gaap	Liabilities Liabilities	440223	USD
CY2021Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.00001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	322574504	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	292815960	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	3221	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	2925	USD
CY2021Q3	xeri	Common Stock To Be Issued CommonStockToBeIssued	1263400	shares
CY2021Q2	xeri	Common Stock To Be Issued CommonStockToBeIssued	51090	shares
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4138194	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3270235	USD
CY2021Q2	xeri	Controlling Interest ControllingInterest	921992	USD
CY2021Q3	us-gaap	Minority Interest MinorityInterest	-1394502	USD
CY2021Q2	us-gaap	Minority Interest MinorityInterest	-216686	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35970	USD
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	29541	USD
CY2020Q3	us-gaap	Professional Fees ProfessionalFees	20600	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	122688	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	705306	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	489868	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1145529	USD
CY2021Q3	us-gaap	Marketing Expense MarketingExpense	598595	USD
CY2020Q3	us-gaap	Marketing Expense MarketingExpense	0	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1201002	USD
CY2021Q3	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	82500	USD
CY2020Q3	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	36500	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2340575	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	4252213	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	93070	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4252213	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-93070	USD
CY2021Q3	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	149028	USD
CY2020Q3	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	45961	USD
CY2021Q3	us-gaap	Legal Fees LegalFees	43750	USD
CY2020Q3	us-gaap	Legal Fees LegalFees	45961	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	2389	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	1087	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-535	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-186954	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-195702	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-234002	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1177816	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	0	USD
CY2021Q3	xeri	Common Stockholders CommonStockholders	-3270099	USD
CY2020Q3	xeri	Common Stockholders CommonStockholders	0	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4447915	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-327072	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	225497197	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118378360	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	705306	USD
CY2021Q3	xeri	Issuance Of Common Stock Committed In Prior Period Amount IssuanceOfCommonStockCommittedInPriorPeriodAmount	0	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1668500	USD
CY2021Q3	xeri	Shares Issued As Equity Kicker Amount SharesIssuedAsEquityKickerAmount	43753	USD
CY2021Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	128550	USD
CY2021Q3	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	173070	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	541100	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	1060324	USD
CY2021Q3	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	250000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4447915	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	122688	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-31224	USD
CY2020Q3	xeri	Common Stock Issued For Prior Period Conversions Of Principal And Interest Amount CommonStockIssuedForPriorPeriodConversionsOfPrincipalAndInterestAmount	0	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	51145	USD
CY2020Q3	xeri	Conversion Of Series A Preferred To Common Stock Amount ConversionOfSeriesAPreferredToCommonStockAmount	0	USD
CY2021Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	250000	USD
CY2020Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	79300	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2047090	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	79300	USD
CY2021Q3	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-680693	USD
CY2020Q3	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	3165	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	962540	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38893	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	281847	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-27398	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4447915	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-327072	USD
CY2020Q3	xeri	Relative Fair Value Warrants Issued With Convertible Debt RelativeFairValueWarrantsIssuedWithConvertibleDebt	36407	USD
CY2020Q3	xeri	Fair Value Of Beneficial Conversion Feature Associated With Convertible Debt FairValueOfBeneficialConversionFeatureAssociatedWithConvertibleDebt	42893	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	200454	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-327073	USD
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1060324	USD
CY2021Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1668500	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2021Q3	xeri	Stock Issued For Services StockIssuedForServices	494700	shares
CY2021Q3	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	149028	USD
CY2020Q3	xeri	Amortization Of Debt Discount AmortizationOfDebtDiscount	45961	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-535	USD
CY2020Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q3	xeri	Cash From Exercise Of Warrants CashFromExerciseOfWarrants	128549	USD
CY2020Q3	xeri	Cash From Exercise Of Warrants CashFromExerciseOfWarrants	0	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-186954	USD
CY2021Q3	xeri	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	-155	USD
CY2020Q3	xeri	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	262	USD
CY2020Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	572	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	17188	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2727742	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76135	USD
CY2021Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	139674	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42058	USD
CY2021Q3	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020Q3	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021Q3	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	187246	USD
CY2020Q3	xeri	Conversion Of Convertible Notes Payable And Accrued Interest ConversionOfConvertibleNotesPayableAndAccruedInterest	51145	USD
CY2021Q3	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	117893	USD
CY2020Q3	xeri	Warrants Issued With Convertible Notes Payable WarrantsIssuedWithConvertibleNotesPayable	36402	USD
CY2021Q3	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	171957	USD
CY2020Q3	xeri	Beneficial Conversion Feature Arising From Convertible Notes Payable BeneficialConversionFeatureArisingFromConvertibleNotesPayable	42893	USD
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	158196	USD
CY2021Q3	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	250000	USD
CY2021Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.</p>
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2340575	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2021Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	168087	USD
CY2020Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	0	USD
CY2021Q3	xeri	Income Tax Positions Percentage Description IncomeTaxPositionsPercentageDescription	greater than 50% likely
CY2021Q3	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.10	pure
CY2021Q3	us-gaap	Prepaid Rent PrepaidRent	4659	USD
CY2021Q3	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	31847	USD
CY2021Q3	xeri	Office Lease OfficeLease	220448	USD
CY2021Q3	xeri	Less Accumulated Amortization LessAccumulatedAmortization	-61061	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	159387	USD
CY2021Q3	xeri	Office Leas OfficeLeas	173826	USD
CY2021Q3	xeri	Less Current Portion LessCurrentPortion	-44160	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129667	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	44266	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	60392	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	62201	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	37112	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	203971	USD
CY2021Q3	xeri	Present Value Discount PresentValueDiscount	-30144	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	173826	USD
CY2021Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	139674	USD
CY2021Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	158196	USD
CY2021Q3	xeri	Total Face Value TotalFaceValue	250000	USD
CY2021Q2	xeri	Total Face Value TotalFaceValue	167550	USD
CY2021Q3	xeri	Less Unamortized Discount LessUnamortizedDiscount	-110326	USD
CY2021Q2	xeri	Less Unamortized Discount LessUnamortizedDiscount	-9354	USD
CY2021Q3	xeri	Debt Instrument Convertible Beneficial Conversion Feature For Future DebtInstrumentConvertibleBeneficialConversionFeatureForFuture	2539	USD
CY2021Q3	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	0	USD
CY2020Q3	xeri	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	1957	USD
CY2021Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
CY2020Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	30	USD
CY2021Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4185000	shares
CY2021Q3	xeri	Common Stock Issued For Prior Period Conversions Principal And Interest CommonStockIssuedForPriorPeriodConversionsPrincipalAndInterest	10598544	shares
CY2021Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	167550	USD
CY2021Q3	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	4985	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-535	USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2021Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.00001
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	19000000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2375000	shares
CY2021Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y9M18D
CY2021Q3	us-gaap	Cash Cash	281847	USD
CY2021Q2	us-gaap	Cash Cash	962540	USD
CY2021Q2	xeri	Working Capital Deficit WorkingCapitalDeficit	677257	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-327072	USD
CY2021Q3	xeri	Shares Sold SharesSold	31466666	shares
CY2021Q3	xeri	Proceeds From Issuance Of Common Stocks ProceedsFromIssuanceOfCommonStocks	1572500	USD
CY2021Q3	xeri	Warrants Issued24 WarrantsIssued24	4308600	shares

Files In Submission

Name	View Source	Status
0001477932-21-008723-index-headers.html	Edgar Link	pending
0001477932-21-008723-index.html	Edgar Link	pending
0001477932-21-008723.txt	Edgar Link	pending
0001477932-21-008723-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xeri-20210930.xsd	Edgar Link	pending
xeri-20210930_cal.xml	Edgar Link	unprocessable
xeri-20210930_def.xml	Edgar Link	unprocessable
xeri-20210930_lab.xml	Edgar Link	unprocessable
xeri-20210930_pre.xml	Edgar Link	unprocessable
xeri_10q.htm	Edgar Link	pending
xeri_10q_htm.xml	Edgar Link	completed
xeri_ex311.htm	Edgar Link	pending
xeri_ex312.htm	Edgar Link	pending
xeri_ex321.htm	Edgar Link	pending
xeri_ex322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERI
XERIANT, INC. Stock $xeri

2021 Q4 Form 10-Q Financial Statement

#000147793221008723 Filed on November 22, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI XERIANT, INC. Stock $xeri

2021 Q4 Form 10-Q Financial Statement

#000147793221008723 Filed on November 22, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERI
XERIANT, INC. Stock $xeri